Citations

Clear

4610 citation(s) found for "Lu, Brian".

Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies
Lan, Qing , Morton, Lindsay M. , Hartge, Patricia, Menashe, Idan , Zheng, Tongzhang, Purdue, Mark P. , Cerhan, James R. , Grulich, Andrew E. , Holford, Theodore R. , Vajdic, Claire M. , Leaderer, Brian P., Kricker, Anne , Schenk, Maryjean, Zahm, Shelia Hoar , Chatterjee, Nilanjan , Rothman, Nathaniel , Wang, Sophia , Armstrong, Bruce K. , Zhang, Yawei , Cozen, Wendy , Yeager, Meredith , Davis, Scott , Chanock, Stephen Jacob , Cerhan, James R , Vajdic, Claire M , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Blood | May 4, 2009 | Volume: 114 | Issue: 2 | Pages: 264-267

10.1182/blood-2009-01-198697 | PMID 19414860 Get It

Abstract Caspases play a critical role in regulation of apoptosis, cell differentiation, inflammation, and innate immunity, and several are mutated or have altered expression in non-Hodgkin lymphoma (NHL). To study the impact of genetic variation in caspases on NHL risk, we analyzed tag single nucleotide polymorphisms (SNPs) in 12 caspase and related genes in 3 population-based case-control studies (1946 cases and 1808 controls). Gene-based analysis, adjusting for the number of tagSNPs genotyped in each gene, showed significant associations for CASP8, CASP9, and CASP1. SNP-based analysis showed that CASP8 rs6736233 (odds ratio (OR) CG = 1.21; ORCC = 2.13; P trend = .011); CASP9 rs4661636 (ORCT = 0.89; ORTT = 0.77; P trend = .011); and CASP1 rs1785882 (ORAT = 1.12; ORAA = 1.30; P trend = .0054) were significantly associated with NHL risk and consistent across studies. It is noteworthy that genetic variants in CASP8 were associated with risk of all major NHL subtypes. Our findings suggest that genetic variation in caspases may play an important role in lymphomagenesis.
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Roccaro, Aldo M. , Sacco, Antonio , Thompson, Brian , Leleu, Xavier , Azab, Feda, Runnels, Judith, Jia, Xiaoying , Ngo, Hai T., Melhem, Molly, Lin, Charles P. , Rollins, Barrett J. , Azab, Abdel Kareem , Ribatti, Doménico , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M

Mayo Clinic

Blood | April 29, 2009 | Volume: 113 | Issue: 26 | Pages: 6669-6680

10.1182/blood-2009-01-198408 | PMID 19401561 Get It

Abstract Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of MM at the epigenetic level and specifically how microRNAs regulate MM progression in the context of the bone marrow milieu. Therefore, we performed microRNA expression profiling of bone marrow derived CD138+ MM cells versus their normal cellular counterparts and validated data by qRT-PCR. We identified a MM-specific microRNA signature characterized by down-expression of microRNA-15a/-16 and overexpression of microRNA-222/-221/-382/-181a/-181b (P < .01). We investigated the functional role of microRNA-15a and -16 and showed that they regulate proliferation and growth of MM cells in vitro and in vivo by inhibiting AKT serine/threonine-protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-κB-activator MAP3KIP3. Moreover, miRNA-15a and -16 exerted their anti-MM activity even in the context of the bone marrow milieu in vitro and in vivo. These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM.
Risk of Non–Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development
Morton, Lindsay M. , Purdue, Mark P. , Zheng, Tongzhang, Wang, Sophia , Menashe, Idan , Chatterjee, Nilanjan , Lan, Qing , Vajdic, Claire M. , Severson, Richard K., Holford, Theodore R. , Kricker, Anne , Cerhan, James R. , Leaderer, Brian P., Grulich, Andrew E. , Zahm, Shelia Hoar , Rothman, Nathaniel , Hartge, Patricia, Armstrong, Bruce K. , Zhang, Yawei , Davis, Scott , Yeager, Meredith , Cozen, Wendy , Chanock, Stephen Jacob , Cerhan, James R , Vajdic, Claire M , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 8, 2009 | Volume: 18 | Issue: 4 | Pages: 1259-1270

10.1158/1055-9965.epi-08-1037 | PMID 19336552 Get It

AbstractChromosomal translocations are the hallmark genetic aberration in non–Hodgkin lymphoma (NHL), with specific translocations often selectively associated with specific NHL subtypes. Because many NHL-associated translocations involve cell cycle, apoptosis, and lymphocyte development regulatory genes, we evaluated NHL risk associated with common genetic variation in 20 candidate genes in these pathways. Genotyping of 203 tag single nucleotide polymorphisms (SNP) was conducted in 1,946 NHL cases and 1,808 controls pooled from 3 independent population-based case-control studies. We used logistic regression to compute odds ratios (OR) and 95% confidence intervals (CI) for NHL and four major NHL subtypes in relation to tag SNP genotypes and haplotypes. We observed the most striking associations for tag SNPs in the proapoptotic gene BCL2L11 (BIM) and BCL7A, which is involved in a rare NHL-associated translocation. Variants in BCL2L11 were strongly related to follicular lymphoma only, particularly rs3789068 (ORAG, 1.41; 95% CI, 1.10-1.81; ORGG, 1.65; 95% CI, 1.25-2.19; Ptrend = 0.0004). Variants in BCL7A were strongly related to diffuse large B-cell lymphoma only, particularly rs1880030 (ORAG, 1.34; 95% CI, 1.08-1.68; ORAA, 1.60; 95% CI, 1.22-2.08; Ptrend = 0.0004). The associations for both variants were similar in all three studies and supported by haplotype analyses. We also observed notable associations for variants in BCL6, CCND1, and MYC. Our results support the role of common genetic variation in cell cycle, apoptosis, and lymphocyte development regulatory genes in lymphomagenesis, and suggest that effects may vary by NHL subtype. Replication of our findings and further study to identify functional SNPs are warranted. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1259–70)
Response to Letter Regarding Article, “Advanced Glycation End Products Accumulate in Vascular Smooth Muscle and Modify Vascular but Not Ventricular Properties in Elderly Hypertensive Canines”
Shapiro, Brian P. , Owan, Theophilus , Mohammed, Selma F. , Meyer, Donna , Redfield, Margaret M. , Mills, Lisa D. , Schalkwijk, Casper G.

Mayo Clinic

Circulation | March 16, 2009 | Volume: 119 | Issue: 10 | Pages: No page available

10.1161/circulationaha.108.833889 Get It

Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer
Schildkraut, Joellen M. , Goode, Ellen L. , Clyde, Merlise A. , Iversen, Edwin S., Moorman, Patricia G. , Marks, Jeffrey R. , Lissowska, Jolanta , Brinton, Louise A. , Pepłońska, Beata , Cunningham, Julie M. , Vierkant, Robert A. , Rider, David N., Chenevix‐Trench, Georgia , Webb, Penelope M. , Beesley, Jonathan, Chen, Xiaoqing, Phelan, Catherine, Sutphen, Rebecca , Sellers, Thomas A. , Pearce, Leigh, Wu, Anna H. , Conti, David V. , Elund, Christopher K., Anderson, Rebecca L. , Goodman, Marc T. , Lurie, Galina, Carney, Michael E., Thompson, Pamela J., Gayther, Simon A. , Ramus, Susan J. , Jacobs, Ian , Kjær, Susanne K. , Høgdall, Estrid , Blaakær, Jan , Høgdall, Claus , Easton, Douglas F. , Song, Honglin , Whittemore, Alice S. , McGuire, Valerie , Quaye, Lydia, Terry, Kathryn L. , Hankinson, Susan E. , Tworoger, Shelley S. , García‐Closas, Montserrat , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Berchuck, Andrew , Chen, Xiaoqing, Berg, David Van Den , Pharoah, Paul D.P. , Anton‐Culver, Hoda , Ziogas, Argyrios , Cramer, Daniel W. , Calingaert, Brian , Chanock, Stephen Jacob , Sherman, Mark E. , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Webb, Penelope M , Vierkant, Robert A , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Conti, David V , Goodman, Marc T

Mayo Clinic

Cancer Research | March 10, 2009 | Volume: 69 | Issue: 6 | Pages: 2349-2357

10.1158/0008-5472.can-08-2902 | PMID 19276375 Get It

Abstract The p53 protein is critical for multiple cellular functions including cell growth and DNA repair. We assessed whether polymorphisms in the region encoding TP53 were associated with risk of invasive ovarian cancer. The study population includes a total of 5,206 invasive ovarian cancer cases (2,829 of which were serous) and 8,790 controls from 13 case-control or nested case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Three of the studies performed independent discovery investigations involving genotyping of up to 23 single nucleotide polymorphisms (SNP) in the TP53 region. Significant findings from this discovery phase were followed up for replication in the other OCAC studies. Mixed effects logistic regression was used to generate posterior median per allele odds ratios (OR), 95% probability intervals (PI), and Bayes factors (BF) for genotype associations. Five SNPs showed significant associations with risk in one or more of the discovery investigations and were followed up by OCAC. Mixed effects analysis confirmed associations with serous invasive cancers for two correlated (r2 = 0.62) SNPs: rs2287498 (median per allele OR, 1.30; 95% PI, 1.07–1.57) and rs12951053 (median per allele OR, 1.19; 95% PI, 1.01–1.38). Analyses of other histologic subtypes suggested similar associations with endometrioid but not with mucinous or clear cell cancers. This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region. [Cancer Res 2009;69(6):2349–57]
ACGME competencies in neurology
Kash, Kathryn M., Leas, Brian F , Clough, John D., Capobianco, David J., Nash, D. B., Bance, Lucila O. , Nash, David B. , Dodick, David W. , Nash, D. B.

Mayo Clinic

Neurology | March 9, 2009 | Volume: 72 | Issue: 10 | Pages: 893-898

10.1212/01.wnl.0000344164.98457.bf | PMID 19273822 Get It

Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Sargent, Daniel J. , Köhne, Claus Henning, Sanoff, Hanna K. , Bot, Brian M. , Seymour, Michel , Gramont, Aimery de , Porschen, R, Saltz, Leonard B. , Rougier, Philippe, Tournigand, C., Douillard, Jean‐Yves , Grothey, Axel, Goldberg, Richard M. , Stephens, Richard J. , Sargent, Daniel J , Saltz, Leonard , Seymour, Matthew T , Sanoff, Hanna

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 12 | Pages: 1948-1955

10.1200/jco.2008.20.2879 | PMID 19255311 Get It

PurposePerformance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.Patients and MethodsIndividual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade ≥ 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy.ResultsCompared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade ≥ 3 nausea (8.5% v 16.4%, respectively; P < .0001) and vomiting (7.6% v 11.9%, respectively; P = .006) and 60-day all-cause mortality (2.8% v 12.0%, respectively; P < .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P < .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P < .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P < .0001; 43.8% for PS 0 or 1 v 32.0% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients.ConclusionIn clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.
Membrane Protein Targeting to the MVB/Lysosome
Davies, Brian A., Lee, Jacqueline, Oestreich, Andrea J., Katzmann, David J.

Mayo Clinic

Chemical Reviews | February 25, 2009 | Volume: 109 | Issue: 4 | Pages: 1575-1586

10.1021/cr800473s | PMID 19243135 Get It

Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders
Magaña, Setty M. , Matiello, Marcelo , Pittock, Sean J. , McKeon, Andrew , Lennon, Vanda A. , Shuster, Elizabeth A., Kantarci, Orhun H. , Lucchinetti, Claudia F. , Weinshenker, Brian G. , Rabinstein, Alejandro A. , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

Neurology | February 23, 2009 | Volume: 72 | Issue: 8 | Pages: 712-717

10.1212/01.wnl.0000343001.36493.ae | PMID 19237699 Get It

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
Friedberg, Jonathan W. , Cerhan, James R. , Flowers, Christopher R. , Dillon, Hildy, Rogers, Eric S., Hainsworth, John D. , Wong, Elaine K., Zelenetz, Andrew D. , Link, Brian K. , Taylor, Michael D. , Farber, Charles Michael , Vose, Julie M. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D

Mayo Clinic

Journal of Clinical Oncology | February 9, 2009 | Volume: 27 | Issue: 8 | Pages: 1202-1208

10.1200/jco.2008.18.1495 | PMID 19204203 Get It

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. Patients and Methods The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention. Results Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy. Conclusion Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.